Hmm, I might even suggest that this trial has a disproportionate number of HIGH CD4 cell count patients. If at baseline in that study, lymphocyte counts were between 331 and 4,736, with medians of 1,044 for those below 200 CD4 at 2 months and 1,645 for those above 200 CD4, and it states that after SOC:
Then, if they fell on average 72% for the 1,645 median group and 49% for the 1,044 group when checked at 2 months after SOC, then their medians were 460 and (oddly) 532 respectively, after SOC. So, only the upward bounds would get into the DCVax-L trial.
I just noticed IMUC's trial did NOT have this inclusion criteria:
but rather:
However this may have removed a number of them, as they are prone to infections (the study noted a decent % of them acquiring pneumonia):
The question is, how will including only HIGH lymphocyte functioning patients affect PFS/OS rates of control? Adjust modeling?